Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

March 2019; 6 (2) Clinical/Scientific NotesOpen Access

pRNFL as a marker of disability worsening in the medium/long term in patients with MS

Christian Cordano, Bardia Nourbakhsh, Michael Devereux, Vincent Damotte, Daniel Bennett, Stephen L. Hauser, Bruce A. C. Cree, Jeffrey M. Gelfand, Ari J. Green
First published December 21, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000533
Christian Cordano
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bardia Nourbakhsh
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Devereux
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Damotte
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Bennett
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen L. Hauser
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce A. C. Cree
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey M. Gelfand
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ari J. Green
From the Department of Neurology (C.C., M.D., V.D., D.B., S.L.H., B.A.C.C., J.M.G., A.J.G.), UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA; and Department of Neurology (B.N.), Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
pRNFL as a marker of disability worsening in the medium/long term in patients with MS
Christian Cordano, Bardia Nourbakhsh, Michael Devereux, Vincent Damotte, Daniel Bennett, Stephen L. Hauser, Bruce A. C. Cree, Jeffrey M. Gelfand, Ari J. Green
Neurol Neuroimmunol Neuroinflamm Mar 2019, 6 (2) e533; DOI: 10.1212/NXI.0000000000000533

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
564

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

MS is an inflammatory and neurodegenerative disease of the CNS (including the retina) that leads to progressive neurologic disability. Disability correlates with the degree of axonal pathology in the disease.1,2 The clinical course of MS is unpredictable, making the search for biomarkers associated with enhanced risk of disease progression a major unmet need. Spectral domain optical coherence tomography (SD-OCT) is a potential predictor of disability worsening up to 5 years of follow-up after a single evaluation of the peripapillary retinal nerve fiber layer (pRNFL).3 Time domain OCT (TD-OCT) is an older technology, characterized by lower axial resolution and slower acquisition speed (400 axial scans per second) resulting in lower resolution images and more frequent motion artifacts compared with SD-OCT.4 TD-OCT was used over 10 years ago to assess retinal neurodegeneration in patients with MS but only now has enough time passed to assess its actual predictive potential for clinical progression.

To investigate the capacity of TD-OCT measures to predict disability worsening in patients with MS, we performed a retrospective evaluation of 305 patients with MS (228 relapsing-remitting, 29 secondary progressive, 32 clinically isolated syndrome, 10 primary progressive MS according to 2005 McDonald criteria,5 and 6 with MS but unclear disease course) who had undergone Stratus TD-OCT (Carl Zeiss Meditec AG, Jena, Germany) from January 2006 to December 2008, collecting the values of the pRNFL and macular volume (MV). The Committee on Human Research at UCSF approved the study. All participants provided written informed consent. The baseline cohort characteristics are presented in the table. All patients had at least 1 measurement of the Expanded Disability Status Scale (EDSS) during the subsequent follow-up period. In our analyses, we used the most recent available EDSS. The median follow-up duration from the time of OCT to the most recent EDSS evaluation was 7.9 years (interquartile range 6.4–8.9 years, range 0.04–9.5 years); 91% of the cohort had >5 years of follow-up. The association between the baseline pRNFL and the subsequent EDSS was investigated using multivariable linear regression, adjusted for age and sex, taking into account the correlation of pRNFL thickness in the patient's 2 eyes (figure). For each 1-μm decrease in the pRNFL, there was a 0.024 increase in EDSS (95% CI: 0.011–0.037; p < 0.001). In a sensitivity analysis, the results were similar (0.022 increase in the EDSS, 95% CI 0.035–0.01, p = 0.001) when analyzing only patients with >5 years of follow-up. A model adjusted for the presence of previous episodes of optic neuritis yielded similar results (a 1-μm decrease in the RNFL was associated with a 0.024 increase in the EDSS; p < 0.001). There was no association with MV. The lack of consistent association of MV with disability worsening has previously been reported3 and may relate to the lack of segmentation from whole macular thickness where some layers increase volume and others lose volume during the course of disease. In addition, TD-OCT had poorer reproducibility for volume scans because of the low speed of image acquisition. These results show that TD-OCT and a single evaluation of pRNFL atrophy is useful in predicting disability up to 6–9 years later in MS—significantly longer than has been previously reported. A limitation of the study is the absence of the baseline EDSS in the entire cohort, which limited our ability to consider its influence as a confounder in the estimate of association between the baseline RNFL and subsequent EDSS. Recent meta-analyses show that the mean RNFL loss in a population of patients with optic neuritis is similar between TD-OCT and SD-OCT.6,7 However, despite the similarity in means at an individual level, SD-OCT is known to be more accurate. Stratus TD-OCT is no longer used in MS research because of the availability of more sophisticated OCT machines being able to quantify retinal measures with a much lower level of noise.8 Nevertheless, despite the effect on SDs, this noise does not affect the mean, and data from earlier iterations of the technology can be useful to indicate the association between retinal thinning and future disability.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Demographic and baseline characteristics and the follow-up data of the study population (number of patients = 305)

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Association of baseline RNFL with EDSS at the end of the follow-up period

RNFL = retinal nerve fiber layer.

Author contributions

C. Cordano: study concept and design, interpretation of data, and composition of the manuscript. B. Nourbakhsh: analysis and interpretation of data. M. Devereux and V. Damotte: acquisition of data and composition of the manuscript. D. Bennett: acquisition of data and supervision of the manuscript. S.L. Hauser and B.A.C. Cree: study supervision and composition of the manuscript. J.M. Gelfand: analysis and interpretation of data and composition of the manuscript. A.J. Green: study concept and design, analysis and interpretation of data, and composition of the manuscript.

Study funding

No targeted funding reported.

Disclosure

C. Cordano received research support from FISM and served as a consultant for Inception 5. B. Nourbakhsh received research support from Biogen, American Brain Foundation, National Multiple Sclerosis Society, and Patient-Centered Outcome Research Institute. M. Devereux reports no disclosures. V. Damotte received travel funding from ECTRIMS and ARSEP Foundation. D. Bennett reports no disclosures. S.L. Hauser served on the scientific advisory boards of Symbiotix, Annexon, Bionure, Molecular Stethoscope, Alector, and Neurona; received travel funding and speaker honoraria from F. Hoffmann La Roche; receives publishing royalties from McGraw-Hill Education; received writing support from F. Hoffmann La Roche; and received research support from the NIH, NMSS, and Conrad N. Hilton Foundation. B.A.C. Cree served on the scientific advisory board of Akili and consulted for AbbVie, Biogen, EMD Serono, GeNeuro, Novartis, and Sanofi Genzyme. J.M. Gelfand served on the DSMB for an NIA-funded study; is on the editorial board of Neurology: Neuroimmunology & Neuroinflammation; received publishing royalties from DynaMed Plus; consulted for Biogen; received research support from MedDay and research support (to UCSF) from Genentech; is PI of an institutional clinician training award from the NMSS; received compensation for medical-legal consulting; his spouse is an associate editor of JAMA Neurology; received honoraria from UpToDate; and consulted for Zosano, Eli Lilly, Biohaven, and eNeura. A.J. Green served on the scientific advisory boards of MedImmune, Novartis, Inception 5 Sciences, Pipeline, and Bionure; served as an associate editor of JAMA Neurology and editorial board member of Neurology; holds a patent for remyelination molecules and pathways; received research support from Novartis, Inception Sciences, NINDS, NIA, NIH, NMSS, Sherak Foundation, and Hilton Foundation; holds stock or stock options in Inception 5, Pipeline, and Bionure; and served as an expert witness in Mylan Pharmaceuticals v Teva Pharmaceuticals. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

  • The Article Processing Charge was funded by the authors.

  • Received July 19, 2018.
  • Accepted in final form November 8, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Arnold DL,
    2. Matthews PM,
    3. Francis G,
    4. Antel J
    . Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154–159.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Frohman EM,
    2. Costello F,
    3. Stüve O, et al
    . Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008;65:26–35.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Martinez-Lapiscina EH,
    2. Arnow S,
    3. Wilson JA, et al
    . Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol 2016;15:574–584.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Leung CK,
    2. Chiu V,
    3. Weinreb RN, et al
    . Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography. Ophthalmology 2011;118:1558–1562.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Polman CH,
    2. Reingold SC,
    3. Edan G, et al
    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840–846. Review.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Petzold A,
    2. de Boer JF,
    3. Schippling S, et al
    . Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9:921–932.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Petzold A,
    2. Balcer LJ,
    3. Calabresi PA, et al
    . Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2017;16:797–812.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Warner CV,
    2. Syc SB,
    3. Stankiewicz AM, et al
    . The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One 2011;6:e22947.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Neuro-ophthalmology
  • Multiple sclerosis
  • Optic nerve

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise